Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

CONCLUSIONS: In this updated analysis of the ARROW study, pralsetinib continued to show deep and durable clinical activity and a manageable safety profile in patients with advanced/metastatic RET-altered thyroid cancer.PMID:38009200 | DOI:10.1089/thy.2023.0363

Source: Thyroid : official journal of the American Thyroid Association - November 27, 2023 Category: Endocrinology Authors: Vivek Subbiah Mimi I Hu Aaron S Mansfield Matthew H Taylor Martin Schuler Viola W Zhu Julien Hadoux Giuseppe Curigliano Lori Wirth Justin F Gainor Guzman Alonso Douglas R Adkins Yann Godbert Myung-Ju Ahn Philippe A Cassier Byoung Chul Cho Chia-Chi Lin Ale Source Type: research